Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT05503953

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Conditions: Essential Hypertension

Sex: All

Ages: 19 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 318

Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd

Location: AhnGook Seoul

Summary

A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS

Eligibility Criteria

Inclusion Criteria: * Hypertension patient who satisfied below condition at Visit 1. * patient who takes antihypertensive drug * 140mmHg \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05503953). StuddyBuddy aggregates publicly available trial information.